SCHEMBL1937751

SCHEMBL1937751

NCc1ncccc1C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.53
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 3/20 0.49
HSD17B10 Q99714 3/20 0.49
SYK P43405 3/20 0.48
NAPRT Q6XQN6 1/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
AHR P35869 1/20 0.44
P2RX7 Q99572 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
TSHR P16473 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
BLM P54132 1/20 0.41
AGER Q15109 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732196 0.85 PARP1 (0.50) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL497429 0.85 PARP1 (0.53) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5196284 0.85 PARP1 (0.53) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2300950 0.85 NAPRT (0.58) KDM4EALDH1A1NAPRTMAPTRAB9A
SCHEMBL28139294 0.83 PARP1 (0.45) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30666151 0.83 PARP1 (0.51) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL353231 0.83 KDM4E (0.55) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30011332 0.83 KDM4E (0.55) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL31439135 0.83 PARP1 (0.51) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3664193 0.83 PARP1 (0.51) PARP1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2736886-B1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2016-09-14 EP disclosed
US-9024022-B2 Substrates of O6-alkylguanine-DNA alkyltransferase and mutants thereof CIS BIO INTERNATIONAL (FR) 2015-05-05 US disclosed
EP-2331510-B1 SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT) AND THEIR USE IN METHOD OF LABELLING ION BEAM APPLIC SA (BE) 2013-11-06 EP disclosed
US-20110236952-A1 NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF CIS BIO INTERNATIONAL (FR) 2011-09-29 US disclosed
EP-2331510-A1 NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF CIS Bio International (FR) 2011-06-15 EP disclosed
WO-2010034931-A1 NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF CIS-BIO INTERNATIONAL (FR) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110236952-A1 NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF OGG1, UNG, MPG PARP1 921/4885KDM4E 3591/4885ALDH1A1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.